Entrada Therapeutics Inc (TRDA) Stock Price, Quote & News

Company Profile

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 520 9158

Website: www.entradatx.com

Address:

One Design Center Place, Suite 17- 500, Boston, United States

Spacerobot Jun. 4 at 8:56 PM

$TRDA Gonna blast up tomorrow and into next week.

0 · Reply

SuperGreenToday Jun. 3 at 5:22 AM

$TRDA Share Price: $6.64 Contract Selected: Dec 18, 2026 $5 Calls Buy Zone: $2.26 – $2.79 Target Zone: $4.20 – $5.13 Potential Upside: 76% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

nightstocker15 May. 29 at 4:03 PM

$TRDA we want 10 and soon 🙌🔥🎉💪

0 · Reply

nightstocker15 May. 28 at 7:41 PM

$TRDA just nice and steady stair stepping higher 💪👀🔥

0 · Reply

ScorpionScarlet May. 22 at 2:35 PM

$TRDA another beauty 🍾🥂💕💸

0 · Reply

nightstocker15 May. 22 at 2:21 PM

$TRDA break through 7 next 💪🎉

0 · Reply

nightstocker15 May. 21 at 9:36 PM

$TRDA insiders loading up, wonder if we start to see more rolling in! Take advantage! strong buy 💪👀🙌

0 · Reply

ScorpionScarlet May. 21 at 8:40 PM

$TRDA oh director bought shares 💕 something good will happen🥳💰

0 · Reply

nightstocker15 May. 21 at 3:31 PM

$TRDA curling up 👀! Let’s start the move to 10 💪

0 · Reply

ScorpionScarlet May. 21 at 1:47 PM

$TRDA slowly going up when shorts asleep😆🥳💕

0 · Reply

Entrada Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 2, 2026, 7:00 AM EDT - 2 days ago

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 10 mg/kg in Entrada Therapeutics' ELEVATE-45-201 Study

Jun 1, 2026, 4:30 PM EDT - 3 days ago

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 19, 2026, 10:00 AM EDT - 16 days ago

Entrada Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 11, 2026, 10:40 AM EDT - 24 days ago

Entrada Therapeutics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-05-08T19:22:05.000Z - 27 days ago

Entrada Therapeutics price target lowered to $10 from $19 at Roth Capital

NVS

2026-05-08T10:33:55.000Z - 27 days ago

Entrada Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

2026-05-07T18:55:28.000Z - 4 weeks ago

Entrada Therapeutics reports topline data from Cohort 1 of ELEVATE-44-201 study

2026-05-07T12:38:27.000Z - 4 weeks ago

Entrada Therapeutics reports Q1 EPS (95c), consensus ($1.02)

May 7, 2026, 8:30 AM EDT - 4 weeks ago

Entrada Therapeutics Transcript: Study result

May 7, 2026, 8:30 AM EDT - 4 weeks ago

Entrada Therapeutics Press release: Study result

May 7, 2026, 8:30 AM EDT - 4 weeks ago

Entrada Therapeutics Slides: Study result

May 7, 2026, 7:10 AM EDT - 4 weeks ago

Entrada Therapeutics Reports First Quarter 2026 Financial Results

May 7, 2026, 7:04 AM EDT - 4 weeks ago

Entrada's Duchenne drug shown to improve muscle function in early trial

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Entrada Therapeutics Announces Positive Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Entrada Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 4 weeks ago

Entrada Therapeutics Earnings release: Q1 2026

May 6, 2026, 4:30 PM EDT - 4 weeks ago

Entrada Therapeutics to Announce Topline Results from Cohort 1 of Participants with Duchenne Muscular Dystrophy Treated with ENTR-601-44 in Phase 1/2 ELEVATE-44-201 Study on May 7, 2026

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

Entrada Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Entrada Therapeutics Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 5 weeks ago

Entrada Therapeutics Proxy statement: Proxy filing

2026-04-06T12:05:42.000Z - 2 months ago

Entrada Therapeutics price target raised to $23 from $21 at Oppenheimer

2026-04-01T11:04:15.000Z - 2 months ago

Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-04-01T10:34:05.000Z - 2 months ago

Entrada Therapeutics initiated with an Overweight at Cantor Fitzgerald

2026-03-30T15:35:39.000Z - 2 months ago

Entrada Therapeutics management to meet with Oppenheimer

Mar 3, 2026, 2:30 PM EST - 3 months ago

Entrada Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-27T12:54:27.000Z - 3 months ago

Entrada Therapeutics price target raised to $19 from $13 at Roth Capital

2026-02-26T12:07:36.000Z - 3 months ago

Entrada Therapeutics reports Q4 EPS (94c), consensus ($1.24)

Feb 26, 2026, 7:00 AM EST - 3 months ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Feb 26, 2026, 7:00 AM EST - 3 months ago

Entrada Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 3 months ago

Entrada Therapeutics Annual report: Q4 2025

2026-02-17T12:10:30.000Z - 3 months ago

Entrada announces DMC recommends initiation of Cohort 2 in ELEVATE-44-201 study

Feb 17, 2026, 7:00 AM EST - 3 months ago

Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 Study

Feb 11, 2026, 4:00 PM EST - 4 months ago

Entrada Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

2026-02-11T11:10:24.000Z - 4 months ago

Entrada Therapeutics initiated with a Buy at Guggenheim

2026-02-10T21:27:46.000Z - 4 months ago

Entrada Therapeutics initiated with a Buy at Guggenheim

Feb 4, 2026, 7:00 AM EST - 4 months ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

2026-01-28T12:35:11.000Z - 4 months ago

Entrada Therapeutics initiated with an Outperform at Oppenheimer

Jan 14, 2026, 6:45 PM EST - 5 months ago

Entrada Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:00 AM EST - 5 months ago

Entrada Therapeutics Slides: Corporate presentation

2026-01-08T12:16:10.000Z - 5 months ago

Entrada Therapeutics reports progress across development portfolio

Jan 8, 2026, 7:00 AM EST - 5 months ago

Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases

Dec 17, 2025, 7:00 AM EST - 6 months ago

Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-11-06T23:40:23.000Z - 7 months ago

Entrada Therapeutics price target lowered to $13 from $17 at Roth Capital

2025-11-06T12:50:18.000Z - 7 months ago

Entrada Therapeutics files $400M mixed securities shelf

2025-11-06T12:16:45.000Z - 7 months ago

Entrada Therapeutics reports Q3 EPS ($1.06), consensus (96c)

Nov 6, 2025, 7:00 AM EST - 7 months ago

Entrada Therapeutics Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 7:00 AM EST - 7 months ago

Entrada Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Entrada Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 7 months ago

Entrada Therapeutics Registration statement: Registration Filing

Sep 25, 2025, 10:00 AM EDT - 9 months ago

Entrada Therapeutics Transcript: H.C.Wainwright @ Home Fireside Chat

Sep 25, 2025, 7:00 AM EDT - 9 months ago

Entrada Therapeutics Slides: International Conference on Muscle Wasting Presentation

2025-09-17T08:30:14.000Z - 9 months ago

Entrada Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

Sep 8, 2025, 7:00 AM EDT - 9 months ago

Entrada Therapeutics Slides: Corporate Presentation

Sep 5, 2025, 7:00 AM EDT - 9 months ago

Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant Program

Aug 18, 2025, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Slides: FY 2025

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Earnings release: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Quarterly report: Q2 2025

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Entrada Therapeutics Slides: Q2 2025

Jul 21, 2025, 2:00 AM EDT - 11 months ago

Entrada Therapeutics Slides: 6th International Caparica Conference on Splicing Presentation

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Entrada Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 11:05 AM EDT - 1 year ago

Entrada Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 12:00 PM EDT - 1 year ago

Entrada Therapeutics Slides: Corporate Presentation

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Entrada Therapeutics Proxy statement: Proxy Filing

Jun 3, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

BIIB

May 28, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

May 22, 2025, 2:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: FY 2025

May 20, 2025, 2:00 PM EDT - 1 year ago

Entrada Therapeutics Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 14, 2025, 2:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: 28th Annual ASGCT Meeting Presentation

May 8, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Reports First Quarter 2025 Financial Results

May 7, 2025, 6:00 PM EDT - 1 year ago

Entrada Therapeutics Earnings release: Q1 2025

May 7, 2025, 6:00 PM EDT - 1 year ago

Entrada Therapeutics Quarterly report: Q1 2025

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 3, 2025, 2:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: 2nd Peptide-Based Therapeutics Summit Presentation

Mar 26, 2025, 3:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: 4th Novel Conjugates Summit Presentation

Mar 26, 2025, 3:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: FY 2025

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Annual report: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Slides: Q4 2024

Feb 24, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Feb 3, 2025, 7:00 AM EST - 1 year ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Jan 30, 2025, 4:05 PM EST - 1 year ago

Azenta Announces the Election of Dipal Doshi to its Board of Directors

AZTA

Jan 15, 2025, 2:15 PM EST - 1 year ago

Entrada Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 2:15 PM EST - 1 year ago

Entrada Therapeutics Slides: FY 2025

Dec 18, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 12:30 PM EST - 1 year ago

Entrada Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 5, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 7:00 AM EST - 1 year ago

Entrada Therapeutics Slides: Q3 2024

Oct 9, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Sep 24, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Sep 17, 2024, 8:30 AM EDT - 1 year ago

āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to its Board of Directors

Sep 9, 2024, 12:30 PM EDT - 1 year ago

Entrada Therapeutics Transcript: H.C. Wainwright 26th Annual Global Investment Conference

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Entrada Therapeutics Slides: Corporate Presentation

Jun 24, 2024, 7:15 AM EDT - 2 years ago

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Slides: Corporate Presentation

Jun 24, 2024, 6:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Jun 10, 2024, 4:00 PM EDT - 2 years ago

Entrada Therapeutics Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 3, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

May 16, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

May 7, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports First Quarter 2024 Financial Results

May 7, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Quarterly report: Q1 2024

May 7, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Earnings release: Q1 2024

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 19, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Earnings release: Q4 2023

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Entrada Therapeutics Annual report: Q4 2023

Mar 13, 2024, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Nov 22, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy

Nov 7, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Quarterly report: Q3 2023

Nov 7, 2023, 7:00 AM EST - 2 years ago

Entrada Therapeutics Earnings release: Q3 2023

Sep 21, 2023, 7:00 AM EDT - 2 years ago

Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Appoints Gina Chapman to its Board of Directors

Aug 8, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports Second Quarter 2023 Financial Results

Aug 8, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Quarterly report: Q2 2023

Aug 8, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Earnings release: Q2 2023

Jun 14, 2023, 1:40 PM EDT - 3 years ago

Entrada Therapeutics Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

Jun 6, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference

May 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Reports First Quarter 2023 Financial Results

May 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Quarterly report: Q1 2023

May 10, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Earnings release: Q1 2023

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 25, 2023, 8:00 AM EDT - 3 years ago

Entrada Therapeutics Proxy statement: Proxy Filing

Apr 4, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors

Mar 29, 2023, 7:00 AM EDT - 3 years ago

Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference

Mar 6, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 6, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics Earnings release: Q4 2022

Mar 6, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics Annual report: Q4 2022

Feb 27, 2023, 7:00 AM EST - 3 years ago

Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Spacerobot Jun. 4 at 8:56 PM

$TRDA Gonna blast up tomorrow and into next week.

0 · Reply

SuperGreenToday Jun. 3 at 5:22 AM

0 · Reply

nightstocker15 May. 29 at 4:03 PM

$TRDA we want 10 and soon 🙌🔥🎉💪

0 · Reply

nightstocker15 May. 28 at 7:41 PM

$TRDA just nice and steady stair stepping higher 💪👀🔥

0 · Reply

ScorpionScarlet May. 22 at 2:35 PM

$TRDA another beauty 🍾🥂💕💸

0 · Reply

nightstocker15 May. 22 at 2:21 PM

$TRDA break through 7 next 💪🎉

0 · Reply

nightstocker15 May. 21 at 9:36 PM

$TRDA insiders loading up, wonder if we start to see more rolling in! Take advantage! strong buy 💪👀🙌

0 · Reply

ScorpionScarlet May. 21 at 8:40 PM

$TRDA oh director bought shares 💕 something good will happen🥳💰

0 · Reply

nightstocker15 May. 21 at 3:31 PM

$TRDA curling up 👀! Let’s start the move to 10 💪

0 · Reply

ScorpionScarlet May. 21 at 1:47 PM

$TRDA slowly going up when shorts asleep😆🥳💕

0 · Reply

theBigDollarski May. 19 at 3:03 PM

$TRDA started a position at 5.70, a rather large position.

0 · Reply

nightstocker15 May. 14 at 5:55 PM

$IPHA hell of a move! Keep an eye on $TRDA conference next Tuesday 👀🔥 and way oversold! Trades thin and can run hard! 💪

0 · Reply

nightstocker15 May. 14 at 3:39 PM

$TRDA drop on low volume, buying here 💪

0 · Reply

MarketBeat May. 9 at 6:07 AM

Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile $TRDA https://www.marketbeat.com/instant-alerts/entrada-t

0 · Reply

Youngmoney22choppa May. 7 at 9:17 PM

$TRDA well considering I swung trade it for a profit today I think I’m fine

0 · Reply

NotHopeJustFacts May. 7 at 8:43 PM

$TRDA what a POS, this would go BK in no time, smart money know this and this is why 50% with not so bad news, classic biotech scam

0 · Reply

Spacerobot May. 7 at 8:06 PM

$TRDA How's enTURDa doing?

0 · Reply

Vinny16 May. 7 at 6:19 PM

$TRDA lol newbie

0 · Reply

Messerschmittbf109 May. 7 at 5:17 PM

$TRDA will close -70 -80% .. I’ll buy around 2… Wen they will buy will be the enter point Great insiders …

0 · Reply

Messerschmittbf109 May. 7 at 4:57 PM

$TRDA Entrada's stock craters as DMD data underperform expectations, handing advantage to Novartis

0 · Reply

BioTuesdays May. 7 at 3:56 PM

$TRDA has announced positive topline data from Cohort 1 of the double-blind, placebo-controlled, multiple ascending dose portion of the Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44 in ambulatory participants ages four to 20 with a confirmed mutation in the DMD gene amenable to exon 44 skipping. https://biotuesdays.com/2026/05/07/entrada-reveals-positive-topline-results-from-study-of-entr-601-44-in-dmd/

0 · Reply

dao4570 May. 7 at 3:22 PM

$TRDA This seems to be an over reaction. I’m up almost 20%!

0 · Reply

Market Cap	257.77M
Revenue (ttm)	25.42M
Net Income (ttm)	-143.75M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-565.50%
Debt to Equity Ratio	0.00

Volume	235,300
Avg Vol	397,982
Day's Range	N/A - N/A
Shares Out	38.82M
Stochastic %K	83%
Beta	-0.26
Analysts	Strong Sell
Price Target	$17.67